awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
Graphs
1
Q27852806-076927B9-E1A9-42D7-B9D1-D445FCE839EC
Q27852806-076927B9-E1A9-42D7-B9D1-D445FCE839EC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27852806-076927B9-E1A9-42D7-B9D1-D445FCE839EC
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
P3181
Q27852806-076927B9-E1A9-42D7-B9D1-D445FCE839EC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27852806-076927B9-E1A9-42D7-B9D1-D445FCE839EC
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
968823696ffa9d6bcb559d5e797fe6181b2192d6
P3181
559999
http://www.w3.org/2001/XMLSchema#string
P3181
559999